Cubist gets Dificid, tedizolid in deal for Optimer, Trius

|About: Optimer Pharmaceuticals, Inc. (OPTR)|By:, SA News Editor

With the deal for Optimer (OPTR), Cubist (CBST) gets the antibacterial drug Dificid, which it has co-promoted with OPTR since 2011. CEO Michael Bonney notes that the co-promotion experience combined with CBST's "outstanding hospital-based commercial infrastructure," should allow for the maximization of the drug's potential.

Previously, some worried disappointing Q1 Dificid sales ($16.8M versus estimates of ~$20M) would make OPTR less attractive as a takeout target.

In the Trius (TSRX) deal, CBST gets the antibiotic tedizolid phosphate (developed with Bayer outside the U.S.), a phase IV treatment for Gram-positive infections.